Medeiros et al 1 recently reported their results of allogeneic BMT in 16 patients with Fanconi's anemia (FA) using cyclophosphamide (CY) only as conditioning with a total dose of 100 mg/kg. One striking observation in this study is that no patient developed hemorrhagic cystitis.
Hemorrhagic cystitis (HC) has long been recognized as a major toxicity post BMT for FA patients. In an effort to identify the optimal dose of CY for patients with FA undergoing BMT, we began a new protocol using 15 mg/kg of CY daily for 4 consecutive days (total of 60 mg/kg) in addition to antithymocyte globulin but with no radiation therapy. Prophylaxis for hemorrhagic cystitis consisted of vigorous hydration for 4 h before and 4 h after each dose of CY. In addition, Mesna was given at 5 mg/kg i.v. prior to each dose of CY, and repeated at a dose of 2 mg/kg every 4 h for five doses after CY (total Mesna dose, 15 mg/kg/day). We have to date transplanted three patients; all engrafted, but two developed severe hemorrhagic cystitis, and although the cystitis resolved in both patients, they nevertheless required prolonged hospitalization and suffered significant morbidity. As a result of this, we have recently modified our protocol to begin the hydration earlier and continue for 7 days after the last dose of CY.
In We recently reported our experience using the KholiKumar protocol, 6 where one patient out of 19 also developed HC.
The severity of the DNA repair defect varies in different families suffering from FA, and this may explain the different incidence of HC in the series reported.
M Ayas
King Recently, Auerbach 4 published the data obtained from a joint study with our group, where the genomic DNA from 84 FA patients was studied. FANCA mutation screening identified 52 patients (62%) in FA-A, and there is a trend suggesting that most FA patients in Brazil have a better prognosis, similar to FANCC patients with exon 1 mutation.
Thus it seems that Ayas and Mustafa are correct when they speculated a distinct sensitivity to cytotoxic agents among FA patients, as we have also done. Mismatched related cord blood transplantation in a severe thalassemia patient
In Southeast Asia, ␤-thalassemia, and hemoglobin (Hb) E are common. The frequencies of the traits can be as high as 3-9% for ␤ 0 thalassemia, and up to 54% or higher for Hb E. 1 Patients with ␤-thalassemia/Hb E can be as severely affected as those with homozygous ␤-thalassemia or Cooley's anemia. At present, allogeneic hematopoietic stem cell transplantation is the only curative therapy for thalassemia. Issaragrisil et al 2 were the first to report successful use of matched related cord blood transplantation (CBT) in a child with ␤-thalassemia/Hb E disease. In the published literature review, all thalassemic patients treated with CBT received fully matched cord blood (CB). [3] [4] [5] [6] We report our experience of utilizing mismatched CBT in a child with severe ␤-thalassemia/Hb E disease.
A 3-year-old female was diagnosed with ␤ 0 -thalassemia/Hb E at 4 months of age when she presented with anemia. Her steady-state hemoglobin level was 7 gm/dl. The result of hemoglobin typing was: Hb F 58.2%, Hb E 41.8%. The patient required packed red blood cell transfusion on three occasions. Her father had ␤-thalassemia trait and her mother had Hb E trait. Analysis of ␤ globin gene mutation demonstrated a nonsense mutation at codon 17. The patient's HLA typing was: A 2,10; B 62,46; Cw 1,6; Bw 6, −; DR B1* 1502,1401; DR 51,52; DQ A1* 0101,0104; DQ B1* 0501,0502.
During a subsequent maternal pregnancy, cord blood was collected at the time of delivery. The male fetus was homozygous for wild-type ␤-thalassemia gene. The volume of collected cord blood was 150 ml. The total numbers of nucleated cells and CD34 + cells were 6.1 × 10 7 cells/kg and 1.58 × 10 5 cells/kg, respectively. Cord blood typing was: A 10,11; B 62,48; Cw 6,8; Bw 6, -; DR B1* 1502,1401; DR 51,52; DQ A1* 0101,0104; DQ B1* 0501,0503 (HLA class I by serology, and class II by high resolution sequencespecific primer DNA typing). The patient shared one haplotype with his brother. However, no mismatch in HLA-DR B1* and HLA-DQ A1* was noted. Due to inability to access international bone marrow donor registries from Thailand, we decided to perform CBT instead of a matched unrelated BMT in this patient. The preparative regimen consisted of busulfan (BU) 5 mg/kg/day (day −11 to day −8), cyclophosphamide 50 mg/kg/day (day −7 to day −4), and antithymocyte globulin (ATG) 20 mg/kg/day (day −3 to day −2). The viability of CB at the time of infusion was 86%. GVHD prophylaxis comprised methylprednisolone (1 mg/kg/day) starting on day −1 for 30 days and cyclosporin A starting on day −1 at a dose of 3 mg/kg i.v. every 12 h until day +30 when it was given orally for 6 months.
Neutrophil engraftment (ANC Ͼ0.5 × 10 9 /l) occurred on day +25, and platelet engraftment (Ͼ20.0 × 10 9 /l) on day +60. She became red blood cell transfusion independent on day +72. Her course of CBT was complicated by acute GVHD grade II. However, it resolved with ATG and methylprednisolone administration. A chimerism study performed on day +240 showed full donor chimerism. This was detected by a FISH technique using probes for the X and Y chromosomes which showed Y (donor) cells 99.4% and XX cells (recipient) 0.6%. There was also a switch in blood group from AB+ pre transplant to B+ post transplant. Serial hemoglobin levels and hemoglobin typing are summarized in Table 1 . Unfortunately on day +300 the patient died of Salmonella sepsis. She had also developed limited chronic GVHD and she was receiving steroids at the time of death from sepsis.
We believe that performing this CBT early in the disease course and thus avoiding frequent blood transfusion, adding ATG, and using GVHD prophylaxis without methotrexate allowed a successful engraftment in this case. An identical HLA-DR locus between donor and recipient may have contributed to excellent engraftment with minimal rejection. GVHD and using a cord blood graft in this patient may have contributed to delayed immune reconstitution. This Table 1 Serial hemoglobin levels and hemoglobin typing pre and post cord blood transplantation (CBT) 
